SUDO 550
Alternative Names: SUDO-550Latest Information Update: 02 Jan 2024
At a glance
- Originator Sudo Biosciences
- Class Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple sclerosis; Neurodegenerative disorders
Most Recent Events
- 02 Jan 2024 Preclinical trials in Multiple sclerosis in USA (PO) (Sudo Biosciences pipeline, January 2024)
- 02 Jan 2024 Preclinical trials in Neurodegenerative disorders in USA (PO) (Sudo Biosciences pipeline, January 2024)
- 28 Mar 2023 Sudo Biosciences has patent protection for substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors in USA